Stapokibart治疗6-11岁中重度特应性皮炎儿童的开放标签单臂Ib/IIa期试验
该药为抗IL-4Rα单抗,已在中国获批用于成人中重度特应性皮炎。本试验纳入25例6-11岁患儿,按体重分层给药8周并随访8周。结果显示耐受性尚可,EASI-75在两组分别为54%和75%,未见治疗相关抗药抗体,需更大规模对照研究确认长期获益。
要点
- 按体重分层给药方案在儿童中显示初步疗效与耐受性。
- EASI-75应答率:30-60kg组54%(7/13),15-30kg组75%(9/12)。
- 未检测到治疗相关抗药抗体,无新安全信号。
核心结论
- Stapokibart在6-11岁中重度特应性皮炎患儿中显示改善病情的潜力和良好的耐受性。
研究设计与样本
- 多中心开放标签单臂Ib/IIa期试验(NCT06162507),治疗8周、随访8周。
- 共25例6-11岁中重度AD患儿接受皮下注射,按体重分层给药。
主要发现
- 68%的患儿报告轻中度不良事件。
- 第8周EASI较基线改善≥75%的比例:30-60kg组54%(7/13),15-30kg组75%(9/12)。
- 首次给药后药物浓度快速上升,重复给药进一步升高,停药后逐渐下降。
- 两组炎症生物标志物均下降,未检测到治疗相关抗药抗体。
关键数值与推荐
- 30-60kg组:300mg每3周一次共3次(含600mg负荷剂量)。
- 15-30kg组:150mg每2周一次共4次(含300mg负荷剂量)。
临床怎么用
- 目前数据支持该药在儿童中进一步开展对照研究,暂不足以指导常规临床用药决策。
局限性
- 开放标签单臂设计、样本量小(25例),缺乏对照组。
- 治疗和随访时间较短(各8周),长期疗效与安全性未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stapokibart is a novel anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To assess the safety, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of stapokibart in children with moderate-to-severe AD. METHODS: This was a multicentre open-label single-arm phase Ib/IIa trial (NCT06162507) involving 8 weeks of treatment and 8 weeks of follow-up. Children aged 6-11 years received subcutaneous stapokibart based on a bodyweight-tiered regimen (30-60 kg: 300 mg every 3 weeks for a total of three doses, including a 600-mg loading dose; 15-30 kg: 150 mg every 2 weeks for a total of four doses, including a 300-mg loading dose). RESULTS: Twenty-five patients (13 weighing 30-60 kg; 12 weighing 15-30 kg) received stapokibart; 68% reported mild or moderate adverse events. At week 8, 54% (n = 7/13) of those weighing 30-60 kg and 75% (n = 9/12) of those weighing 15-30 kg achieved a ≥ 75% improvement from baseline in Eczema Area and Severity Index. Stapokibart concentrations increased rapidly following the first dose, climbed further with repeated dosing and gradually declined after treatment discontinuation. Stapokibart reduced inflammatory biomarkers in both groups. No treatment-related antidrug antibodies were detected. No new safety signals emerged. CONCLUSIONS: Stapokibart shows potential in improving disease outcomes and appears to be well tolerated in children aged 6-11 years with moderate-to-severe AD. Larger controlled studies are needed to confirm long-term benefits. Atopic dermatitis, also known as eczema, is a long-term condition. It causes dry, red, itchy and inflamed areas of skin. Eczema affects about 2 in 10 of children worldwide. It can seriously affect people’s health and quality of life. There are not many safe and effective long-term treatments for young children with moderate-to-severe disease. A new medication called stapokibart is approved in China to treat adults with moderate-to-severe eczema. In this study, we tested how safe and effective stapokibart is in treating children with moderate-to-severe eczema. Twenty-five children aged 6 to 11 were given stapokibart injections for 8 weeks. The amount of the medication they were given depended on how much they weighed. The children were divided into two groups. The first group included 13 children who weighed 30 to 60 kilograms. The other group included 12 children who weighed 15 to 30 kilograms. Seventeen of the 25 children experienced side effects. All the side effects were mild or moderate. At the end of the study, scoring systems were used to assess how severe the children’s eczema was. Using a scoring system called the ‘EASI’, more than half of children who weighed 30 to 60 kilograms had a 75% improvement in the severity of their eczema. In the group of children weighing 15 to 30 kilograms, three quarters of them also achieved this improvement. Another scoring system used to assess disease severity is called the ‘IGA’. Using this system, almost a quarter of all the children in the study saw an improvement in their disease. We also measured how itchy the children were. At the end of the study, a reduction in itchiness was seen in both groups of children. Finally, we also assessed the children’s quality of life, using a scoring system called the Children’s Dermatology Life Quality Index. Using this, we found that children in both groups experienced an improvement in their quality of life. Blood tests were also done. The results of these tests showed that the children had reduced inflammation. No antibodies called ‘ADAs’ were found. ADAs can significantly affect how a medicine is processed by the body. The results suggest that stapokibart may be a potential new treatment for children with AD. Larger and longer studies are needed to confirm these findings. They will also need to determine any long-term effects of stapokibart in children with AD.
引用
- Zhao M, Xu Z, Wu L, et al. Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6-11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial. Br J Dermatol. 2026. PMID: 41284735. doi:10.1093/bjd/ljaf455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。